{"title":"低血糖的神经后果和糖尿病神经病变的发病机制。","authors":"S Heller, J D Ward","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Although the limitations of human experimental models of hypoglycemia have hampered investigation, it is generally accepted that a reversible deterioration in cognitive function occurs at a plasma glucose concentration of around 3.5 mmol/L, above the glycemic threshold for symptoms. It is unclear whether this threshold varies in those with hypoglycemia unawareness. Repeated severe hypoglycemia may cause chronic impairment although the clinical significance and the contribution of other factors remains unclear. There is increasing evidence that microvascular abnormalities are the major factor in the pathogenesis of peripheral neuropathy. This may be why there is still little experimental support from human clinical studies for the use of aldose reductase inhibitors in its treatment.</p>","PeriodicalId":77089,"journal":{"name":"Current opinion in neurology and neurosurgery","volume":"6 3","pages":"423-8"},"PeriodicalIF":0.0000,"publicationDate":"1993-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Neurologic consequences of hypoglycemia and pathogenic mechanisms involved in diabetic neuropathy.\",\"authors\":\"S Heller, J D Ward\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Although the limitations of human experimental models of hypoglycemia have hampered investigation, it is generally accepted that a reversible deterioration in cognitive function occurs at a plasma glucose concentration of around 3.5 mmol/L, above the glycemic threshold for symptoms. It is unclear whether this threshold varies in those with hypoglycemia unawareness. Repeated severe hypoglycemia may cause chronic impairment although the clinical significance and the contribution of other factors remains unclear. There is increasing evidence that microvascular abnormalities are the major factor in the pathogenesis of peripheral neuropathy. This may be why there is still little experimental support from human clinical studies for the use of aldose reductase inhibitors in its treatment.</p>\",\"PeriodicalId\":77089,\"journal\":{\"name\":\"Current opinion in neurology and neurosurgery\",\"volume\":\"6 3\",\"pages\":\"423-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1993-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current opinion in neurology and neurosurgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in neurology and neurosurgery","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Neurologic consequences of hypoglycemia and pathogenic mechanisms involved in diabetic neuropathy.
Although the limitations of human experimental models of hypoglycemia have hampered investigation, it is generally accepted that a reversible deterioration in cognitive function occurs at a plasma glucose concentration of around 3.5 mmol/L, above the glycemic threshold for symptoms. It is unclear whether this threshold varies in those with hypoglycemia unawareness. Repeated severe hypoglycemia may cause chronic impairment although the clinical significance and the contribution of other factors remains unclear. There is increasing evidence that microvascular abnormalities are the major factor in the pathogenesis of peripheral neuropathy. This may be why there is still little experimental support from human clinical studies for the use of aldose reductase inhibitors in its treatment.